5J90.F Fluicell AB (publ)
- Market cap
- EUR 3.35M
- P/E
- 12.8x
- P/B
- 2.26x
- ROE
- 67.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 5J90.F undervalued?
Graham number5J90.F trades 13.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Fluicell AB (publ) fundamental analysis
No fundamental analysis for Fluicell AB (publ) yet.
Fluicell AB (publ) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Fluicell AB (publ)
Fluicell AB (publ), a life science company, develops and provides clay instruments for 3D bioprinting and cell analysis and flow control on single-cell level in Sweden. The company offers BIOPEN, a powerful tool for high precision cell biology that uses open volume microfluidics; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve system, an ion channel screening platform, which allows to record various ion chann…
Full company profileFluicell AB (publ) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Fluicell AB (publ) annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 2.60M | 3.25M | 3.34M | 1.86M | 6.00M | 26.7M |
| Gross Profit | 1.89M | 2.59M | 1.74M | 3.76M | 13.1M | 30.1M |
| Operating Income | -21.7M | -21.7M | -26.9M | -15.8M | -8.40M | 11.1M |
| EBITDA | - | -20.8M | -25.9M | -15.0M | -7.85M | 11.6M |
| Net Income | -21.7M | -21.6M | -26.6M | -15.5M | -8.33M | 11.1M |
| EPS | -132 | -72 | -79 | -11 | -6.07 | 8.11 |
| Balance Sheet | ||||||
| Total Assets | 27.0M | 31.8M | 9.34M | 25.5M | 18.5M | 25.0M |
| Total Liabilities | 7.87M | 8.32M | 8.92M | 6.27M | 7.57M | 8.54M |
| Shareholders' Equity | 19.1M | 23.4M | 425K | 19.2M | 10.9M | 16.5M |
| Cash & Short-term Investments | 20.7M | 24.5M | 2.76M | 15.9M | 2.26M | 30.0K |
| Cash Flow | ||||||
| Operating Cash Flow | -18.6M | -21.0M | -27.2M | -15.7M | -4.94M | -3.69M |
| Capital Expenditure | 772K | 1.14M | 0.00 | 3.49M | 8.67M | 4.82M |
| Free Cash Flow | -19.4M | -22.2M | -27.2M | -19.2M | -13.6M | -8.51M |
| Ratios | ||||||
| ROE | -113.5% | -92.2% | -6,248.0% | -80.6% | -76.4% | 67.6% |
| ROA | -80.4% | -68.0% | -284.3% | -60.8% | -45.1% | 44.5% |
| Net Profit Margin | -833.7% | -664.6% | -795.5% | -834.4% | -138.8% | 41.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Fluicell AB (publ) dividends
Fluicell AB (publ) has not paid dividends in the last 5 fiscal years.
Last stock split: 1:350 on Mar 26, 2025.
Who owns Fluicell AB (publ)
- Insiders 21.15%
- Institutions 8.90%
- Public & others 69.95%
- Shares outstanding 1.37M
- Free float 1.17M
Fluicell AB (publ) company profile
- Company name
- Fluicell AB (publ)
- Ticker
- 5J90.F
- ISIN
- SE0023595459
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 11
- Fiscal year end
- December
- Address
- Flöjelbergsgatan 8C, Mölndal, Sweden, 431 37
- Phone
- 46 735 14 09 91
- Website
- fluicell.com
About Fluicell AB (publ)
Fluicell AB (publ), a life science company, develops and provides clay instruments for 3D bioprinting and cell analysis and flow control on single-cell level in Sweden. The company offers BIOPEN, a powerful tool for high precision cell biology that uses open volume microfluidics; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve system, an ion channel screening platform, which allows to record various ion channel current in patch clamp recording configuration. It also provides Biopixlar, a 3D single-cell bioprinting platform that produces single cell arrays to organoids and complex tissues; Nexocyte, a platform for universal tissue production; and Biopixlar AER, a single-cell bioprinting platform that fits into a biosafety cabinet. Fluicell AB (publ) was incorporated in 2012 and is based in Mölndal, Sweden.
Fluicell AB (publ) management
4- Ms. Carolina TrjuljaChief Executive Officer · born 1984
- Mr. Gavin D. M. JeffriesCo-Founder, CTO & Director · born 1980
- Mr. Joakim WahlbergChief Financial Officer · born 1970
- Mr. Jonas HannestadChief Marketing & Communications Officer · born 1981